

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification : C07H 17/08, A61K 31/70, A61P 31/04	A1	(11) International Publication Number: WO 00/66603 (43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/HR00/00013		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GI, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 2 May 2000 (02.05.00)		
(30) Priority Data: P990130A 3 May 1999 (03.05.99) HR		
(71) Applicant (<i>for all designated States except US</i>): PLIVA, FARMACEUTSKA INDUSTRija, DIONIĆ DRUŠTVO [HR/HR]; ulica grada Vukovara 49, 10000 Zagreb (HR).		
(72) Inventors; and		Published
(75) Inventors/Applicants (<i>for US only</i>): MARUŠIĆ-JŠTUK, Zorica [HR/HR]; Frana Kršinića 11, 10430 Samobor (HR). KUJUNDŽIĆ, Nedjelko [HR/HR]; Slavenskog 4, 10000 Zagreb (HR). KOBREHEL, Gabrijela [HR/HR]; Dobriše Cesarića 8, 10000 Zagreb (HR). MUTAK, Stjepan [HR/HR]; Jagnedje 1, 10000 Zagreb (HR). MARŠIĆ, Nataša [HR/HR]; Nova cesta 1, 10000 Zagreb (HR).		With international search report.
(74) Common Representative: PLIVA, FARMACEUTSKA INDUSTRija, DIONICKO DRUSTVO; Pravni Poslovi, Vesna Vasiljevic, Ulica grada Vukovara 49, 10000 Zagreb (HR).		
(54) Title: HALO DERIVATIVES OF 9-DEOXO-9A-AZA-9A-HOMERYTHROMYCIN A		
<p style="text-align: center;">(I)</p>		
<p style="text-align: center;">(II)</p>		
(57) Abstract		
<p>The invention relates to halo derivatives of 9a-N-(N'-arylcaramoyl)- and 9a-N-(N'- arylthiocaramoyl) -9- deoxo-9a-aza-9a-homoerythromycin A of general formula (I) wherein R has the meaning of a substituted aryl group of formula (II) wherein substituents a, b, c, d and e are the same or different and at least one of them has the meaning of halo, a(C₁-C₆)haloalkyl or a(C₁-C₆)haloalkoxy group, whereas the remaining ones have the meaning of hydrogen, halo, a (C₁-C₆)alkyl or a (C₁-C₆)alkoxy group, and X has the meaning of oxygen or sulfur, and pharmaceutically acceptable addition salts thereof with inorganic or organic acids, to a process for the preparation, of pharmaceutical compositions comprising them and to the use of these pharmaceutical compositions for the treatment or prevention of bacterial infections.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HALO DERIVATIVES OF 9-DEOXO-9A-AZA-9A-HOMERYTHROMYCIN A*1) Technical Field*

A 61 K 31/70, C 07 H 17/08

2) Technical Problem

The invention relates to novel compounds from the class of the macrolide antibiotic erythromycin A. The invention especially relates to halo derivatives of 9a-N-(*N'*-arylcarbamoyl)- and 9a-N-(*N'*-arylthiocarbamoyl)-9-deoxo-9a-aza-9a-homoerythromycin A, to pharmaceutically acceptable addition salts thereof with inorganic or organic acids, to a process for their preparation, to pharmaceutical compositions comprising them and to the use of these pharmaceutical compositions for the treatment or prevention of bacterial infections.

3) Prior Art

Erythromycin A is a macrolide antibiotic whose structure is characterized by a 14-member lactone ring with C-9 ketone, and two sugars, L-cladinose and D-desosamine, glycosidically bound to C-3 and C-5 positions of an aglycone moiety of the molecule (McGuire, *Antibiot. Chemother.*, 1952; 2 : 281). By an oximation of C-9 ketone with hydroxylamine-hydrochloride, Beckmann rearrangement of the obtained 9(*E*)-oxime and reduction of the obtained 6,9-iminoether there is obtained 9-deoxo-9a-aza-9a-homoerythromycin A, the first semisynthetic macrolide with a 15-member azalactone ring (Kobrehel G. et al, US 4,328,334, 5/1982).

By selective acylation of 9-deoxo-9a-aza-9a-homoerythromycin A with carboxylic acid anhydrides, corresponding mono-, di-, tri- or tetraacyl derivatives were synthesized and by a transesterification reaction with ethylene carbonate followed by acylation, 11,12-cyclic carbonate and its acyl derivatives were synthesized (Djokić S. et al, *J. Antibiotics* 40, 1006-1015, 1987).

By reductive methylation of a secondary 9a-amino group of 9-deoxo-9a-aza-9a-homoerythromycin A according to Eschweiler-Clark process, 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A (azithromycin), a prototype of a novel class of 9a-azalide antibiotics (Kobrehel G. et al, BE 892 357, 7/1982) was synthesized. In addition to a broad antimicrobial spectrum also including Gram negative bacteria, azithromycin is characterized by a long biological half-life, a specific mechanism of transport to the application site and a short therapy period. Azithromycin easily penetrates and is accumulated inside human phagocyte cells resulting in an improved action with regard to intracellular pathogenic microorganisms of the classes *Legionella*, *Chlamydia* and *Helicobacter*. Bright G. M. et al (J. Antibiotics 41, 1092-1047, 1987) synthesized a series of 9-a-N-alkyl analogues of azithromycin, disclosed the epimerization of the 4"-hydroxyl group and the preparation of a corresponding 4"-amino derivative.

The synthesis and antibacterial activity of 9a,11-cyclic ethers of 9-deoxo-9a-aza-9a-homoerythromycin A are disclosed in US 4,492,688, 1/1985 (Bright G. M.). The preparation and activity spectrum of 9a,11-cyclic carbamate of 9-deoxo-9a-aza-11-deoxy-9a-homoerythromycin A and its O-methyl derivatives are disclosed in US 5,434,140, 7/1995 (Kobrehel G. et al).

Recently, Blizzard T. A. et al (WO 99/00125, 7/98) disclosed novel 9a-N,6-O-methylene-9-deoxo-9a-aza-9a-homoerythromycin A derivatives and corresponding 9a-N,6-O-carbamates as intermediates in the synthesis of 3-keto derivatives from the class of 9a-azalides.

It has also been disclosed that by a reaction of 9-deoxo-9a-aza-9a-homoerythromycin A with isocyanates or isothiocyanates, corresponding 9a-N-(N'-carbamoyl)- and 9a-N-(N'-thiocarbamoyl) derivatives may be prepared (Kujundžić N. et al, US 5,629,296, 5/97). This invention relates to N'-(C₁-C₃)alkylcarbamoyl, N'-arylcarbamoyl and N'-aralkylcarbamoyl derivatives and to thiocarbamoyl analogues thereof, resp. Although the antibacterial spectrum of these 9a-azalides is similar to the action of azithromycin,


the effectiveness is 2 to 8 times smaller, even in case of the most active representatives (*N'*-naphthylcarbamoyl and *N'*-benzylthiocarbamoyl derivatives).

According to the well-known and established Prior Art, halo derivatives of 9a-*N*-(*N'*-arylcarbamoyl)- and 9a-*N*-(*N'*-arylthiocarbamoyl)-9-deoxo-9a-aza-9a-homoerythromycin A, which are the object of the present invention, pharmaceutically acceptable addition salts thereof with inorganic or organic acids, a process for the preparation thereof, a process for the preparation of pharmaceutical compositions comprising them and the use of these pharmaceutical compositions for the treatment or prevention of bacterial infections have not been disclosed so far.


The object of the present invention is the preparation of novel 9a-*N*-(*N'*-arylcarbamoyl)- and 9a-*N*-(*N'*-arylthiocarbamoyl)-9-deoxo-9a-aza-9a-homoerythromycins A wherein at least one of the substituents on the aromatic ring has the meaning of halo, a (C₁-C₆)haloalkyl or a (C₁-C₆)haloalkoxy group. Novel 9a-azalides of the present invention are characterized by a broad antibacterial spectrum of action including an action upon sensitive and resistent Gram positive and Gram negative microorganisms.

4) The Inventive Solution


It has been found that halo derivatives of 9a-*N*-(*N'*-arylcarbamoyl)- and 9a-*N*-(*N'*-arylthiocarbamoyl)-9-deoxo-9a-aza-9a-homoerythromycin A of the general formula (I)



wherein R has the meaning of a substituted aryl group of the formula (II)



wherein substituents a, b, c, d and e are the same or different and at least one of them has the meaning of halo, a (C_1-C_6)haloalkyl or a (C_1-C_6)haloalkoxy group whereas the remaining ones have the meaning of hydrogen, halo, a (C_1-C_6)alkyl or a (C_1-C_6)alkoxy group, and X has the meaning of oxygen or sulfur, and pharmaceutically acceptable addition salts thereof with inorganic or organic acids, may be prepared by the reaction of 9-deoxo-9a-aza-9a-homoerythromycin A with isocyanates or isothiocyanates of the general formula (III)



wherein R and X have the above meanings, in an aprotic solvent, preferably toluene, at room temperature or at elevated temperature. After the completed reaction the product is isolated by evaporation under reduced pressure and optionally by the use of standard techniques such as chromatography on a silica gel column or recrystallization.

Further, an object of the invention are pharmaceutically acceptable addition salts which, according to recognized medical practice, are non-toxic and in contact with human tissues or tissues of lower mammals do not induce irritation or allergic reactions. The term "pharmaceutically acceptable salts" relates to addition salts of compounds of the general formula (I) with non-toxic inorganic or organic acids. They are prepared *in situ* in the course of isolation or purification of compounds of the invention or subsequently by the reaction of the 3'-dimethylamino group of the isolated base with an at least equimolar amount of the appropriate inorganic or organic acid. Suitable inorganic acids are e.g. hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric or perchloric acid and organic acids are acetic, trifluoroacetic, propionic, benzoic, benzenesulfonic, methanesulfonic, laurylsulfonic, adipic, ascorbic, camphoric, gluconic, fumaric, stearic, palmitic, succinic, ethylsuccinic, lactobionic, oxalic, salicylic acid and similar acids. The reaction of the base with appropriate acids is carried out in an inert solvent and addition salts are isolated by evaporation of solvents or, alternatively, by filtration after a spontaneous precipitation or after precipitation with the addition of a non-polar co-solvent.

Novel halo derivatives of 9a-*N*-(*N'*-arylcarbamoyl)- and 9a-*N*-(*N'*-arylthiocarbamoyl)-9-deoxo-9a-aza-9a-homoerythromycin A of the general formula (I) and pharmaceutically acceptable addition salts thereof with inorganic or organic acids possess an effective antibacterial activity. *In vitro* action of the novel compounds was investigated on a series of standard and resistant test microorganisms. Generally, it was demonstrated by investigating the effectiveness of haloaryl derivatives upon *S. aureus*, *E. faecalis* and *S. pneumoniae* that 9a-*N*-(*N'*-thiocarbamoyl) derivatives were more active than 9a-*N*-(*N'*-carbamoyl) derivatives. *N'*-fluoroaryl derivatives were the most active ones in the series. The position of the substitution did not affect the activity, however, haloarylcarbamoyl derivatives substituted in 2-position were shown to have the best antibacterial *in vitro* activity. In *N'*-(C₁-C₆)haloalkylcarbamoyl derivatives similar traits were observed.

However, in the series of thiocarbamoyl analogues, *N'*-(3-trifluoromethyl) arylthiocarbamoyl derivative was shown to be the most active one and, in addition to

the activity against test microorganisms sensitive to erythromycin, it also showed an activity against resistant strains.

The object of the present invention are also pharmaceutical compositions comprising a therapeutically effective amount of the compounds of the general formula (I) and one or more non-toxic pharmaceutically acceptable carriers. The term "pharmaceutically acceptable carrier" means a non-toxic inert solid, semisolid, liquid filler, diluent etc. Materials that may serve as pharmaceutically acceptable carriers are sugars e.g. lactose, glucose or saccharose, starch, cellulose and its derivatives, e.g. carboxymethyl cellulose or ethyl cellulose, then gelatine, talc, arachis oil, sesame oil, soya-bean oil, glycols e.g. propylene glycol, esters e.g. ethyl acetate or ethyl laurate, agar, buffering agents e.g. magnesium hydroxide or aluminum hydroxide, pyrogen-free water, isotonic solution, Ringer solution, ethanol, phosphate buffer, fragrances, colouring agents, sweeteners etc.

Pharmaceutical compositions of the present invention may be administered orally, parenterally, intravaginally, rectally or intraperitoneally to humans and animals. Liquid formulations for oral application include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to an active component, the liquid formulations may also contain inert diluents e.g. water or other solvents, and various additives. Injection forms e.g. sterile aqueous suspensions are formulated according to well-known processes.

A further object of the invention is a method for the treatment or prevention of bacterial infections in humans and animals, which, in case of need or prophylaxis, includes the application of a therapeutically effective amount of the compound of the general formula (I) for a period of time necessary to achieve a therapeutical action. "A therapeutically effective amount" means a sufficient amount of a substance for the treatment of a bacterial infection in any medical application while carefully observing the interaction of usefulness and risk. The total amount of a daily dosis of compounds of the present invention in applications to humans or animals in a single or a multiple dosis is in the range of from 0.001 to 50 mg/kg of body weight. Generally, the

treatment regimen according to the present invention includes, in case of need, an administration of 10 to 100 mg/day of the compound of the general formula (I) in a single or a multiple dosis.

The process for the preparation of halo derivatives of 9a-*N*-(*N'*-arylcarbamoyl)- and 9a-*N*-(*N'*-aryltiocarbamoyl)-9-deoxo-9a-aza-9a-homoerythromycin A of the present invention is illustrated by the following Examples which should in no way be construed as a limitation thereof.

Example 1

9-deoxo-9a-N-{N'-(2-fluoro-phenyl)carbamoyl]-}9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 2-fluorophenyl-isocyanate (0.61 g; 0.00448 mole) and toluene (40 ml) under stirring for 1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (3.81 g) was obtained. By crystallization from a diethyl ether-petroleum ether mixture a chromatographically homogeneous title product (2.74 g) having the following physico-chemical constants was obtained:

M.p. 129-132°C

IR (KBr) cm^{-1} 3468, 2973, 2937, 1732, 1668, 1619, 1533, 1455, 1380, 1324, 1253, 1167, 1094, 1054, 1013, 958, 897, 834, 753.

FAB-MS 872 [MH⁺]

Example 2

9-deoxo-9a-N-{N'-(2-fluoro-phenyl)thiocarbamoyl]-}9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 2-fluorophenyl-isothiocyanate (0.69 g; 0.00448 mole) and toluene (40 ml) under stirring for 12 hours at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (3.45 g) was obtained. By crystallization from an acetone-petroleum ether mixture a chromatographically homogeneous product (2.05 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3431, 2971, 2936, 1729, 1620, 1514, 1457, 1380, 1314, 1280, 1167, 1094, 1052, 1012, 958, 896, 831, 756.

FAB-MS 888 [MH⁺]

Example 3

9-deoxo-9a-N-{N'-(2-chloro-phenyl)thiocarbamoyl]-}9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 2-chlorophenyl-isothiocyanate (0.76 g; 0.00448 mole) and toluene (40 ml) under stirring for 12 hours

at the temperature of 40°C and by evaporation of the reaction mixture under reduced pressure a crude product (3.51 g) was obtained. By crystallization from an acetone-petroleum ether mixture a chromatographically homogeneous product (2.24 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3411, 2972, 2937, 2058, 1726, 1593, 1520, 1494, 1456, 1379, 1310, 1244, 1168, 1093, 1054, 1014, 958, 897, 834, 754, 735.

FAB-MS 904 [MH⁺]

Example 4

9-deoxo-9a-a-*N*-{*N'*-[(2-chloro-6-methyl-phenyl)carbamoyl]}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (1.5 g; 0.00204 mole), 2-chloro-6-methyl-phenylisocyanate (0.37 g; 0.00228 mole) and toluene (15 ml) under stirring for 1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (1.85 g) was obtained. By chromatography on a silica gel column using the solvent system methylene chloride-methanol 90:5, a chromatographically homogeneous product (1.36 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3437, 2973, 2937, 1732, 1645, 1595, 1510, 1456, 1379, 1280, 1167, 1010, 1053, 1014, 959, 897, 864, 835, 771.

Example 5

9-deoxo-9a-a-*N*-{*N'*-[(3-fluoro-phenyl)carbamoyl]}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 3-fluorophenyl-isocyanate (0.61 g; 0.00448 mole) and toluene (40 ml) under stirring for 1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (3.60 g) was obtained. By crystallization from an acetone-petroleum ether mixture a chromatographically homogeneous product (2.64 g) having the following physico-chemical constants was obtained:

M.p. 140-143°C

IR (KBr) cm⁻¹ 3454, 2975, 2939, 1712, 1651, 1602, 1537, 1494, 1443, 1380, 1317, 1278, 1247, 1167, 1053, 1013, 959, 896, 865, 835, 772, 681.

FAB-MS 872 [MH⁺]

Example 6

9-deoxo-9a-a-N-{N'-(3-chloro-phenyl)carbamoyl]}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 3-chlorophenyl-isocyanate (0.68 g; 0.00448 mole) and toluene (40 ml) under stirring for 1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (3.52 g) was obtained. By crystallization from diethyl ether a chromatographically homogeneous product (1.29 g) having the following physico-chemical constants was obtained:

IR (KBr) cm⁻¹ 3452, 2974, 2939, 2787, 1731, 1669, 1592, 1526, 1484, 1456, 1423, 1380, 1300, 1274, 1246, 1167, 1110, 1013, 958, 897, 834, 775, 681.

¹H NMR (300 MHz, CDCl₃) δ 7.44-6.94 (Ph), 4.93 (H-13), 4.81 (H-1''), 4.42 (H-1'), 4.06 (H-5''), 4.04 (H-3), 3.90 (H-11), 3.83 (H-9a), 3.56 (H-5'), 3.51 (H-5), 3.32 (H-2'), 3.28 (3''-OCH₃), 2.96 (H-4''), 2.70 (H-2), 2.59 (H-3'), 2.46 (H-9b), 2.38 (H-8), 2.36 (3'-N(CH₃)₂), 2.30 (H-2'a), 1.94 (H-14a), 1.89 (H-4), 1.72 (H-4'), 1.58 (H-14b), 1.54 (H-2''b), 1.42 (10-CH₃), 1.27 (2-CH₃), 1.23 (5''-CH₃), 1.21 (3''-CH₃), 1.19 (10-CH₃), 1.17 (12-CH₃), 1.15 (5'-CH₃), 1.07 (4-CH₃), 1.07 (8-CH₃), 0.93 (15-CH₃).

¹³C NMR (75 MHz, CDCl₃) δ 157.0 (9a-NCONH), 176.8 (C-1), 140.5, 134.2, 129.5, 122.4, 119.5, 117.5 (Ph), 104.4 (C-1'), 95.9 (C-1''), 87.8 (C-5), 79.2 (C-3), 78.2 (C-13), 77.4 (C-4''), 74.7 (C-11), 74.5, 74.4 (C-6 and C-12), 72.5 (C-3''), 70.5 (C-2'), 69.1 (C-5'), 65.8 (C-5''), 64.5 (C-3'), 49.1 (3''-OCH₃), 46.3 (C-2), 41.2 (C-4), 40.1 [3'-N(CH₃)₂], 34.7 (C-2''), 29.0 (C-4'), 27.2 (C-8), 21.8 (C-14), 21.3 (8-CH₃), 20.8 (5'-CH₃), 21.1 (3''-CH₃), 17.5 (5''-CH₃), 17.0 (12-CH₃), 15.1 (2-CH₃), 13.1 (10-CH₃), 11.0 (15-CH₃), 9.8 (4-CH₃).

FAB-MS 888.4 [MH⁺]

Example 7

9-deoxo-9a-a-N-{N'-(3-bromo-phenyl)carbamoyl]}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (1.5 g; 0.00204 mole), 3-bromophenylisocyanate (0.44 g; 0.00228 mole) and toluene (20 ml) under stirring for 1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (1.94 g) was obtained. By crystallization from an acetone-petroleum ether mixture a chromatographically homogeneous product having the following physico-chemical constants was obtained:

IR(KBr) cm^{-1} 3446, 3291, 2974, 2936, 1727, 1638, 1582, 1546, 1475, 1418, 1402, 1381, 1312, 1286, 1226, 1167, 1066, 995, 874, 855, 788, 774, 745, 685, 641.

FAB-MS [MH⁺]

Example 8

9-deoxo-9a-N-{N'-(3-fluoro-phenyl)thiocarbamoyl}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 3-fluorophenyl-isothiocyanate (0.6 g; 0.00448 mole) and toluene (40 ml) under stirring for 24 hours at the temperature of 50°C and by evaporation of the reaction mixture under reduced pressure a crude product (3.25 g) was obtained. By chromatography on a silica gel column using the solvent system methylene chloride-methanol 9:1, a chromatographically homogeneous product (1.08 g) having the following physico-chemical constants was obtained:

IR(KBr) cm^{-1} 3435, 2971, 2937, 1728, 1712, 1611, 1515, 1493, 1456, 1379, 1313, 1279, 1168, 1093, 1052, 1011, 959, 896, 832, 778, 727, 636.

FAB-MS 888 [MH⁺]

Example 9

9-deoxo-9a-N-{N'-(3-chloro-phenyl)thiocarbamoyl}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 3-chlorophenyl-isothiocyanate (0.76 g; 0.00448 mole) and toluene (40 ml) under stirring for 24 hours at the temperature of 40°C and by evaporation of the reaction mixture under reduced pressure a crude product (3.51 g) was obtained. By crystallization from diethyl ether a

chromatographically homogeneous product (2.25 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3436, 2974, 2938, 1712, 1683, 1594, 1483, 1460, 1424, 1378, 1308, 1167, 1092, 1053, 1014, 958, 896, 835, 782, 727.

^1H NMR (300 MHz, CDCl_3) δ 7.47-7.12 (Ph), 4.85 (H-1"), 4.81 (H-13), 4.42 (H-1'), 4.11 (H-3), 4.08 (H-5"), 3.50 (H-5'), 3.48 (H-5), 3.29 (3"-OCH₃), 3.25 (H-2'), 3.04 (H-9a), 3.02 (H-4"), 2.80 (H-2), 2.64 (H-10), 2.54 (H-3'), 2.35 (H-2"'), 2.30 (3'-N(CH₃)₂), 1.88 (H-4), 1.78 (H-8), 1.69 (H-4'), 1.29 1.58 (H-14b), 1.56 (H-2"b), 1.32 (6-CH₃), 1.29 (5"-CH₃), 1.29 (12-CH₃), 1.21 (5'-CH₃), 1.21 (2-CH₃), 1.19 (10-CH₃), 1.09 (4-CH₃), 1.08 (3"-CH₃), 0.95 (8-CH₃), 0.91 (15-CH₃).

^{13}C NMR (75 MHz, CDCl_3) δ 183.2 (9a-NSONH), 177.8 (C-1), 141.1, 133.6, 131.0, 129.3, 127.4, 125.7, 123.68 (Ph), 103.8 (C-1'), 95.1 (C-1"), 86.1 (C-5), 79.5 (C-3), 77.9 (C-13), 77.6 (C-4"), 72.4 (C-3"), 70.6 (C-2'), 68.9 (C-5'), 65.4 (C-5"), 64.9 (C-3'), 56.7 (C-9), 56.5 (C-10), 49.2 (3"-OCH₃), 44.9 (C-2), 41.8 (C-7), 41.3 (C-4), 40.2 [3'-N(CH₃)₂], 34.7 (C-2"), 29.3 (C-8), 28.9 (C-4'), 27.0 (6-CH₃), 21.7 (C-14), 21.3 (8-CH₃), 21.2 (5'-CH₃), 21.0 (3"-CH₃), 18.1 (5"-CH₃), 16.9 (12-CH₃), 15.7 (2-CH₃), 14.9 (10-CH₃), 11.0 (15-CH₃), 9.5 (4-CH₃).

FAB-MS 904 [MH⁺]

Example 10

9-deoxo-9a-*N*-{*N'*-[(3-bromo-phenyl)thiocarbamoyl]}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (1.5 g; 0.00204 mole), 97% 3-bromophenylisothiocyanate (0.49 g; 0.00228 mole) and toluene (20 ml) under stirring for 24 hours at the temperature of 60°C and by evaporation of the reaction mixture under reduced pressure a crude product (1.92 g) was obtained. By crystallization from the system acetone-petroleum ether a chromatographically homogeneous product (0.99 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3434, 2970, 2936, 2024, 1730, 1591, 1456, 1379, 1310, 1167, 1093, 1052, 1012, 958, 896, 832, 777, 730, 636.

FAB-MS 948 [MH⁺]

Example 11

9-deoxo-9a-a-N-{N'-(4-chlorophenyl)carbamoyl}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 4-chlorophenylisocyanate (0.68 g; 0.00448 mole) and toluene (40 ml) under stirring for 1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (3.54 g) was obtained. By crystallization from hot acetone a chromatographically homogeneous product (2.16 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3444, 2975, 2938, 1713, 1651, 1593, 1520, 1495, 1457, 1379, 1305, 1244, 1166, 1092, 1053, 1013, 959, 896, 829, 755.

FAB-MS 888.4 [MH^+]

Example 12

9-deoxo-9a-a-N-{N'-(4-bromo-phenyl)carbamoyl}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 4-bromophenylisocyanate (0.89 g; 0.00448 mole) and toluene (40 ml) under stirring for 1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (4.30 g) was obtained. By crystallization from an acetone-petroleum ether mixture a chromatographically homogeneous product (2.20 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3531, 3438, 2977, 2938, 1708, 1683, 1651, 1589, 1520, 1492, 1460, 1377, 1305, 1287, 1244, 1165, 1092, 1053, 1012, 959, 864, 825, 755, 731, 639.

FAB-MS 932 [MH^+]

Example 13

9-deoxo-9a-a-N-{N'-(4-chlorophenyl)thiocarbamoyl}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 4-chlorophenylisothiocyanate (0.76 g; 0.00448 mole) and toluene (40 ml) under stirring for 1 hour at

room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (3.71 g) was obtained. By crystallization from hot acetone a chromatographically homogeneous product (3.26 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3534, 3422, 2978, 2939, 2879, 1699, 1683, 1651, 1586, 1530, 1495, 1461, 1409, 1378, 1310, 1279, 1260, 1229, 1167, 1094, 1052, 1012, 952, 894, 865, 833, 727.

FAB-MS 904 [MH⁺]

Example 14

9-deoxo-9a-N-{N'-(4-bromo-phenyl)thiocarbamoyl]-}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (1.5 g; 0.00204 mole), 4-bromophenylisothiocyanate (0.47 g; 0.00228 mole) and toluene (25 ml) under stirring for 12 hours at the temperature of 50°C and by evaporation of the reaction mixture under reduced pressure a crude product (2.01 g) was obtained. By crystallization from an acetone-petroleum ether mixture a chromatographically homogeneous product (1.92 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3533, 3433, 2974, 2937, 2878, 2786, 1703, 1682, 1626, 1588, 1526, 1492, 1460, 1377, 1312, 1282, 1166, 1093, 1053, 1011, 958, 895, 864, 831, 730.

FAB-MS 948 [MH⁺]

Example 15

9-deoxo-9a-N-{N'-(3-fluoromethyl-4-chloro-phenyl)carbamoyl]-}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (1.5 g; 0.00204 mole), 3-fluoromethyl-4-chlorophenylisocyanate (0.50 g; 0.00228 mole) and toluene (15 ml) under stirring for 1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a product (1.99 g) was obtained. By crystallization from an ethyl

acetate-(n-hexane) mixture a chromatographically homogeneous product (1.28 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3444, 2976, 2940, 1732, 1713, 1663, 1531, 1486, 1456, 1417, 1380, 1325, 1263, 1168, 1135, 1112, 1093, 1053, 1031, 1012, 958, 896, 830.

FAB-MS 956.5 [MH^+]

Example 16

9-deoxo-9a-a-N-{ N' -[(2,4-dichloro-phenyl)carbamoyl]}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (1.5 g; 0.00204 mole), 2,4-dichlorophenylisocyanate (0.41 g; 0.00228 mole) and toluene (15 ml) under stirring for 3 hours at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (1.89 g) was obtained. By crystallization from an ethyl acetate-(n-hexane) mixture a chromatographically homogeneous product (1.14 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3438, 2976, 2939, 1732, 1670, 1651, 1582, 1514, 1487, 1464, 1409, 1381, 1300, 1167, 1053, 1015, 959, 895, 863, 820, 760.

FAB-MS 922.4 [MH^+]

Example 17

9-deoxo-9a-a-N-{ N' -[(2,4-dichloro-phenyl)thiocarbamoyl]}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (1.5 g; 0.00204 mole), 2,4-dichlorophenylisothiocyanate (0.45 g; 0.00228 mole) and toluene (15 ml) under stirring for 7 hours at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (1.96 g) was obtained. By crystallization from an ethyl acetate-(n-hexane) mixture a chromatographically homogeneous product (1.22 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3425, 2975, 2936, 1737, 1590, 1505, 1460, 1379, 1311, 1166, 1092, 1051, 1013, 956, 903, 864, 834, 759, 730.

FAB-MS 938.4 [MH^+]

Example 18

9-deoxo-9a-N-{N'-(2-trifluoromethyl-phenyl)carbamoyl]-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (1.5 g; 0.00204 mole), 2-trifluoromethylphenylisocyanate (0.43 g; 0.0023 mole) and toluene (15 ml) under stirring for 7 hours at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (1.96 g) was obtained. By crystallization from an ethyl acetate-(n-hexane) mixture a chromatographically homogeneous product (1.22 g) having the following physico-chemical constants was obtained:

¹H NMR (300 MHz, CDCl₃) δ 8.06 (9a-NCOMH), 7.57-7.10 (Ph), 5.04 (H-13), 4.82 (H-1"), 4.41 (H-1'), 4.07 (H-5"), 4.05 (H-3), 3.87 (H-11), 3.63 (H-5'), 3.49 (H-5), 3.32 (H-2'), 3.27 (3"-OCH₃), 2.97 (H-4"), 2.68 (H-2), 2.61 (H-3'), 2.38 (H-8), 2.33 (3'-N(CH₃)₂), 2.31 (H-2" a), 1.94 (H-14a), 1.92 (H-4), 1.70 (H-4'), 1.54 (H-2" b), 1.50 (H-14b), 1.39 (10-CH₃), 1.31 (2-CH₃), 1.26 (5"-CH₃), 1.25* (3"-CH₃), 1.22* (12-CH₃), 1.18 (5'-CH₃), 1.06 (4-CH₃), 1.06 (8-CH₃), 0.92 (15-CH₃).

¹³C NMR (75 MHz, CDCl₃) δ 156.8 (9a-NCONH), 176.1 (C-1), 136.7, 132.6, 125.8, 124.4, 123.1 (Ph), 129.7, 126.1, 122.5, 118.9 (CF₃), 104.8 (C-1'), 97.2 (C-1"), 83.2 (C-5), 79.3 (C-3), 77.4 (C-13), 77.9 (C-4"), 74.1 (C-11), 72.5 (C-3"), 70.5 (C-2'), 69.1 (C-5'), 66.0 (C-5"), 64.5 (C-3'), 49.2 (3"-OCH₃), 46.8 (C-2), 41.1 (C-4), 40.2 [3'-N(CH₃)₂], 34.8 (C-2"), 29.4 (C-4'), 27.4 (C-8), 21.9 (C-14), 20.6 (8-CH₃), 21.2 (5'-CH₃), 20.7 (3"-CH₃), 17.6 (5"-CH₃), 17.0 (12-CH₃), 15.5 (2-CH₃), 12.7 (10-CH₃), 11.1 (15-CH₃), 10.2 (4-CH₃).

FAB-MS 922.3 [MH⁺]

Example 19

9-deoxo-9a-N-{N'-(3-trifluoromethyl-phenyl)carbamoyl]-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (7.27 g; 0.00989 mole), 3-trifluoromethylphenylisocyanate (2.43 g; 0.01298 mole) and toluene (40 ml) under stirring for

1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (10.51 g) was obtained. By chromatography on a silica gel column using the system methylene chloride-methanol-conc. ammonia 9:9:1.5, a product (4.1 g) was obtained, which after crystallization from a diethyl ether-petroleum ether mixture had the following physico-chemical constants:

M.p. 122-125°C

IR (KBr) cm^{-1} 3444, 2974, 2939, 1733, 1651, 1544, 1494, 1447, 1380, 1259, 1166, 1125, 1093, 1070, 1053, 1014, 957, 897, 834, 795, 699.

FAB-MS 922.4 [MH^+]

Example 20

9-deoxo-9a-N-{*N'*-[(4-trifluoromethyl-phenyl)carbamoyl]}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (3.0 g; 0.00408 mole), 4-trifluoromethylphenylisocyanate (0.84 g; 0.00448 mole) and toluene (40 ml) under stirring for 1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a precipitate (3.75 g) was obtained. By crystallization from an ethyl acetate-(n-hexane) mixture, from the crude product (1.2 g) the title product (0.99 g) having the following physico-chemical constants was obtained:

IR (KBr) cm^{-1} 3445, 2974, 2939, 1731, 1668, 1602, 1526, 1457, 1413, 1380, 1325, 1249, 1166, 1115, 1068, 1054, 1015, 959, 897, 838.

^1H NMR (300 MHz, CDCl_3) δ 8.25 (9a-NCONH), 7.65-7.20 (Ph), 4.91 (H-13), 4.82 (H-1''), 4.41 (H-1'), 4.03 (H-5''), 4.06 (H-3), 3.91 (H-11), 3.51 (H-5'), 3.54 (H-5), 3.30 (H-2''), 3.28 (3''-OCH₃), 2.97 (H-4''), 2.71 (H-2), 2.55 (H-3'), 2.39 (H-8), 2.31 (3'-N(CH₃)₂), 2.31 (H-2'a), 1.94 (H-14a), 1.88 (H-4), 1.68 (H-4'), 1.55 (H-2'b), 1.56 (H-14b), 1.45 (10-CH₃), 1.26 (2-CH₃), 1.21 (5''-CH₃), 1.21 (3''-CH₃), 1.19 (12-CH₃), 1.11 (5'-CH₃), 1.07 (4-CH₃), 1.08 (8-CH₃), 0.93 (15-CH₃).

^{13}C NMR (75 MHz, CDCl_3) δ 156.9 (9a-NCONH), 171.0 (C-1), 142.6, 125.8, 118.9 (Ph), 124.2, 123.8 (CF₃), 104.3 (C-1'), 96.9 (C-1''), 87.4 (C-5), 79.3 (C-3), 78.3 (C-13), 77.3 (C-4''), 74.8 (C-11), 74.6 (C-6), 74.5 (C-12), 72.5 (C-3''), 70.5 (C-2''), 69.1 (C-5'), 65.8 (C-5''), 64.6 (C-3'), 62.1 (C-10), 49.1 (3''-OCH₃), 46.3 (C-2), 41.1

(C-4), 40.1 [3'-N(CH₃)₂], 34.7 (C-2''), 27.2 (C-4'), 28.8 (C-8), 24.0 (6-CH₃), 21.8 (C-14), 21.3 (8-CH₃), 20.7 (5'-CH₃), 21.1 (3''-CH₃), 17.6 (5''-CH₃), 17.0 (12-CH₃), 15.2 (2-CH₃), 13.2 (10-CH₃), 11.0 (15-CH₃), 9.8 (4-CH₃).

FAB-MS 922.4 [MH⁺]

Example 21

9-deoxo-9a-N-{N'-(3-trifluoromethyl-phenyl)thiocarbamoyl]-}9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (7.27 g; 0.00989 mole), 3-trifluoromethylphenylisothiocyanate (2.64 g; 0.01299 mole) and toluene (40 ml) under stirring for 1 hour at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (9.27 g) was obtained. By crystallization from an acetone-petroleum ether mixture, from the crude product (1.0 g) the title product (0.6 g) having the following physico-chemical constants was obtained:

M.p. 110-112°C

IR (KBr) cm⁻¹ 3454, 2975, 2938, 1734, 1599, 1531, 1494, 1453, 1378, 1331, 1252, 1166, 1124, 1093, 1051, 1012, 957, 904, 698.

¹H NMR (300 MHz, CDCl₃) δ 7.85-7.27 (Ph), 4.86 (H-1''), 4.81 (H-13), 4.43 (H-1'), 4.11 (H-3), 4.07 (H-5''), 3.51 (H-5'), 3.46 (H-5), 3.29 (3''-OCH₃), 3.25 (H-2'), 3.05 (H-9a), 3.04 (H-4''), 2.80 (H-2), 2.58 (H-10), 2.45 (H-3'), 2.35 (H-2'a), 2.30 (3'-N(CH₃)₂), 1.84 (H-9b), 1.93 (H-4), 1.85 (H-14a), 1.75 (H-8), 1.67 (H-4'), 1.29, 1.55 (H-14b), 1.51 (H-2''b), 1.31 (6-CH₃), 1.29 (5''-CH₃), 1.23 (12-CH₃), 1.20 (5'-CH₃), 1.20 (2-CH₃), 1.14 (10-CH₃), 1.09 (4-CH₃), 1.08 (3''-CH₃), 0.94 (8-CH₃), 0.92 (15-CH₃).

¹³C NMR (75 MHz, CDCl₃) δ 183.3 (9a-NSONH), 177.9 (C-1), 140.4, 128.8, 125.7, 123.6, 121.2 (Ph), 131.2, 130.7, 130.3, 129.9 (CF₃), 103.8 (C-1'), 94.9 (C-1''), 86.1 (C-5), 79.4 (C-3), 77.6 (C-4''), 70.5 (C-2'), 69.0 (C-5'), 65.5 (C-5''), 64.8 (C-3'), 56.8 (C-9), 56.6 (C-10), 49.2 (3''-OCH₃), 46.0 (C-2), 40.5 [3'-N(CH₃)₂], 34.6 (C-2''), 29.4 (C-8), 28.8 (C-4'), 21.7 (C-14), 21.3 (8-CH₃), 21.1 (5'-CH₃), 21.6 (3''-CH₃), 18.0 (5''-CH₃), 15.7 (12-CH₃), 14.8 (2-CH₃), 13.5 (10-CH₃), 11.0 (15-CH₃), 9.5 (4-CH₃).

FAB-MS 938.6 [MH⁺]

Example 22

9-deoxo-9a-N-{N'-(2-trifluoromethoxy-phenyl)carbamoyl}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (1.5 g; 0.00204 mole), 2-trifluoromethoxyphenylisocyanate (0.44 g; 0.00228 mole) and toluene (15 ml) under stirring for 3 hours at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (1.94 g) was obtained. By crystallization from an ethyl acetate-(n-hexane) mixture a chromatographically homogeneous product (1.39 g) having the following physico-chemical constants was obtained:

M.p. 126-128°C

IR (KBr) cm⁻¹ 3466, 2974, 2938, 1732, 1669, 1610, 1531, 1455, 1380, 1315, 1250, 1217, 1169, 1109, 1094, 1054, 1013, 958, 897, 836, 758, 630.

FAB-MS 938.5 [MH⁺]

Example 23

9-deoxo-9a-N-{N'-(4-trifluoromethoxy-phenyl)thiocarbamoyl}-9a-aza-9a-homoerythromycin A

From 9-deoxo-9a-aza-9a-homoerythromycin A (1.5 g; 0.00204 mole), 4-trifluoromethoxyphenylisothiocyanate (0.44 g; 0.00228 mole) and toluene (15 ml) under stirring for 2 hours at room temperature and by evaporation of the reaction mixture under reduced pressure a crude product (1.89 g) was obtained. By crystallization from an ethyl acetate-(n-hexane) mixture a chromatographically homogeneous product (1.15 g) having the following physico-chemical constants was obtained:


M.p. 139-141°C

IR (KBr) cm⁻¹ 3456, 2975, 2940, 1731, 1669, 1511, 1457, 1414, 1380, 1265, 1199, 1166, 1111, 1054, 1015, 958, 897, 836.


FAB-MS 938.6 [MH⁺]

CLAIMS

1. Halo derivatives of 9a-N-(N'-arylcarbamoyl)- and 9a-N-(N'-arylthiocarbamoyl)-9-deoxo-9a-aza-9a-homoerythromycin A of the general formula (I)



wherein R has the meaning of a substituted aryl group of the formula (II)



wherein substituents a, b, c, d and e are the same or different and at least one of them has the meaning of halo, a (C₁-C₆)haloalkyl or a (C₁-C₆)haloalkoxy group whereas the remaining ones have the meaning of hydrogen, halo, a (C₁-C₆)alkyl or a (C₁-C₆)alkoxy group, and X has the meaning of oxygen or sulfur, and pharmaceutically acceptable addition salts thereof by inorganic or organic acids.

2. Compounds according to claim 1, characterized in that a has the meaning of halo, b, c, d and e are the same and have the meaning of hydrogen and X is oxygen or sulfur.

3. A compound according to claim 2, characterized in that a has the meaning of fluoro and X is oxygen.

4. A compound according to claim 2, characterized in that a has the meaning of fluoro and X is sulfur.
5. A compound according to claim 2, characterized in that a has the meaning of chloro and X is sulfur.
6. Compounds according to claim 1, characterized in that a has the meaning of halo, b, c and d are the same and have the meaning of hydrogen, e has the meaning of a (C₁-C₄)alkyl group and X is oxygen or sulfur.
7. A compound according to claim 6, characterized in that a has the meaning of chloro, b, c and d are the same and have the meaning of hydrogen, e is methyl and X is oxygen.
8. Compounds according to claim 1, characterized in that a, c, d and e are the same and have the meaning of hydrogen, b is halo and X is oxygen or sulfur.
9. A compound according to claim 8, characterized in that b has the meaning of fluoro and X is oxygen.
10. A compound according to claim 8, characterized in that b has the meaning of chloro and X is oxygen.
11. A compound according to claim 8, characterized in that b has the meaning of bromo and X is oxygen.
12. A compound according to claim 8, characterized in that b has the meaning of fluoro and X is sulfur.
13. A compound according to claim 8, characterized in that b has the meaning of chloro and X is sulfur.

14. A compound according to claim 8, characterized in that b has the meaning of bromo and X is sulfur.
15. Compounds according to claim 1, characterized in that a, b, d and e are the same and have the meaning of hydrogen, c is halo and X is oxygen or sulfur.
16. A compound according to claim 15, characterized in that c has the meaning of chloro and X is oxygen.
17. A compound according to claim 15, characterized in that c has the meaning of bromo and X is oxygen.
18. A compound according to claim 15, characterized in that c has the meaning of chloro and X is sulfur.
19. A compound according to claim 15, characterized in that c has the meaning of bromo and X is sulfur.
20. Compounds according to claim 1, characterized in that a, d and e are the same and have the meaning of hydrogen, b has the meaning of a (C₁-C₆)haloalkyl group, c is halo and X is oxygen or sulfur.
21. A compound according to claim 20, characterized in that a, d and e are the same and have the meaning of hydrogen, b is a -CF₃ group, c is chloro and X is oxygen.
22. Compounds according to claim 1, characterized in that b, d and e are the same and have the meaning of hydrogen, a and c are the same and have the meaning of halo and X is oxygen or sulfur.

23. A compound according to claim 22, characterized in that a and c are the same and have the meaning of chloro and X is oxygen.

24. A compound according to claim 22, characterized in that a and c are the same and have the meaning of chloro and X is sulfur.

25. Compounds according to claim 1, characterized in that a, b, c, d and e are the same or different and have the meaning of hydrogen or of a (C₁-C₄)haloalkyl group and X is oxygen or sulfur.

26. A compound according to claim 25, characterized in that a is a -CF₃ group, b, c, d and e are the same and have the meaning of hydrogen and X is oxygen.

27. A compound according to claim 25, characterized in that a, c, d and e are the same and have the meaning of hydrogen, b is a -CF₃ group and X is oxygen.

28. A compound according to claim 25, characterized in that a, b, d and e are the same and have the meaning of hydrogen, c is a -CF₃ group and X is oxygen.


29. A compound according to claim 25, characterized in that a, c, d and e are the same and have the meaning of hydrogen, b is a -CF₃ group and X is sulfur.

30. Compounds according to claim 1, characterized in that a, b, c, d and e are the same or different and have the meaning of hydrogen or of a (C₁-C₄)haloalkoxy group and X is oxygen or sulfur.


31. A compound according to claim 30, characterized in that b, c, d and e are the same and have the meaning of hydrogen, a is a -OCF₃ group and X is oxygen.

32. A compound according to claim 30, characterized in that a, b, d and e are the same and have the meaning of hydrogen, c is a -OCF₃ group and X is oxygen.


33. Process for the preparation of halo derivatives of 9a-N-(N'-arylcarbamoyl)- and 9a-N-(N'-arylthiocarbamoyl)-9-deoxo-9a-aza-9a-homoerythromycin A of the general formula (I)



wherein R has the meaning of a substituted aryl group of the formula (II)



wherein substituents a, b, c, d and e are the same or different and at least one of them has the meaning of halo, a (C₁-C₆)haloalkyl or a (C₁-C₆)haloalkoxy group whereas the remaining ones have the meaning of hydrogen, halo, a (C₁-C₆)alkyl or a (C₁-C₆)alkoxy group, and X has the meaning of oxygen or sulfur, and pharmaceutically acceptable addition salts thereof with inorganic or organic acids,
characterized in that 9-deoxo-9a-aza-9a-homoerythromycin A is subjected to a reaction with isocyanates or isothiocyanates of the general formula (III)



wherein R and X have the above meanings, in an aprotic solvent, preferably toluene, at room temperature or at elevated temperature.

34. A pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier and an antibacterially effective amount of the compounds according to claim 1.
35. Use of compounds according to any of claims 1 to 32 for the treatment or prevention of bacterial infections.

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/HR 00/00013

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07H17/08 A61K31/70 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07H A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 657 464 A (PLIVA PHARM & CHEM WORKS) 14 June 1995 (1995-06-14) the whole document & US 5 629 296 A 13 May 1997 (1997-05-13) cited in the application -----	1,33-35

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

? Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 July 2000	25/07/2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Scott, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/HR 00/00013

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0657464	A 14-06-1995	HR 931480	A	31-08-1996
		AT 144778	T	15-11-1996
		BG 61571	B	30-12-1997
		BG 99242	A	29-09-1995
		CA 2137395	A	09-06-1995
		CN 1109890	A,B	11-10-1995
		CZ 9403082	A	12-07-1995
		DE 69400817	D	05-12-1996
		DE 69400817	T	22-05-1997
		ES 2096401	T	01-03-1997
		HU 69283	A,B	28-09-1995
		JP 7252292	A	03-10-1995
		PL 306154	A	12-06-1995
		RO 113854	A	30-11-1998
		RU 2131878	C	20-06-1999
		SI 9400434	A	30-06-1995
		SK 146994	A	11-07-1995
		US 5629296	A	13-05-1997